# Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD

> **NCT01213667** · PHASE4 · UNKNOWN · sponsor: **University of Cologne** · enrollment: 110 (estimated)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT01213667
- **Lead sponsor:** University of Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-01
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2016-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01213667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01213667, "Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01213667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*